修改后的Shoutai药丸抑制了铁亡,以减轻重复的妊娠流产
Yuling Lai1, Yu Zhang2, Huimin Zhang2
1Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China; Guangzhou Sport University, Guangzhou, 510500, People's Republic of China.
Journal of ethnopharmacology
|August 19, 2023
概括
建威舒泰药 (JSP) 通过抑制铁亡,有效治疗复发性妊娠失误 (RPL). 这种传统中医药可以改善妊娠的结果,并保护热囊细胞免受铁灭引起的损伤.
科学领域:
- 生殖生物学 生殖生物学
- 分子医学是分子医学.
- 传统中国医药 传统中国医药
背景情况:
- 建伟舒泰药 (JSP) 是一种传统的中医药,用于治疗流产.
- 复发性流产 (RPL) 仍然是一个重要的临床挑战,具有复杂的潜在机制.
研究的目的:
- 调查JSP减轻重复流产的分子机制.
- 为了确定JSP的治疗效果是否涉及抑制铁亡.
主要方法:
- 使用CBA/J交配的DBA/2小鼠建立了RPL的体内小鼠模型,在妊娠期间口服JSP.
- 在体外研究中使用了人类热细胞细胞系HTR-8/SVneo,用铁灭症诱导剂 (RSL3) 和JSP治疗.
- 评估了怀孕结果,铁亡标志物 (铁,MDA,GSH,GPX) 和蛋白质表达 (GPX4,SLC7A11,ACSL4).
主要成果:
- 施用JSP显著改善了体内妊娠结果,降低了吸收率和堕胎率.
- 通过降低铁积累和MDA水平,JSP抑制了铁亡,同时增加了GSH和GPX含量.
- 在体外,JSP保护了热囊细胞免受RSL3引起的损伤,减少了活性氧物种和铁沉积.
结论:
- JSP通过抑制ferroptosis对RPL施加其治疗作用.
- 这项研究为JSP的应用提供了新的见解,用于管理复发性妊娠流产.
更多相关视频
08:45Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
2.0K
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
566
相关概念视频
Infertility in Females
348
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
348
Ovarian Cycle
1.4K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.4K
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Infertility in Males
295
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
295
Hormonal Regulation of the Menstrual Cycle
438
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
438
